Dr. Dinesh Khanna Named, "Doctor Of The Year" PDF Print E-mail
Saturday, 20 August 2011 09:53
The Scleroderma Foundation named Dinesh Khanna, M.D., M.Sc., its 2011 Doctor of the Year during this year's National Patient Education Conference held last month in San Francisco. The award recognizes a skilled physician or researcher for his or her involvement within the Foundation, and for helping provide guidance and support to the organization's patient population.

"Those who know Dr. Khanna as a physician and caretaker know that he is a caring and compassionate doctor who does not lose sight of the fact those patients always come first," said Scleroderma Foundation's CEO Robert J. Riggs. "He is a highly-regarded researcher who is well respected among his peers in the medical community, and his patients also know him as a compassionate physician who always puts their well-being first and foremost."

Dr. Khanna is the Marvin & Betty Danto Research Professor of Connective Tissue Research and Associate Professor of Internal Medicine in the Division of Rheumatology, and the newly-appointed director of the Scleroderma Program at the University of Michigan in Ann Arbor. He previously was the clinical director of the scleroderma clinic at the David Geffen School of Medicine at the University of California at Los Angeles.

He has authored more than 120 peer-reviewed publications and book chapters including a defining paper on gastrointestinal issues in scleroderma. Dr. Khanna received his medical training at the University College of Medical Sciences in New Delhi, India. He completed his residency at Wright State University School of Medicine in Dayton, Ohio, and a fellowship in rheumatology and a Master of Science in Clinical Research at the University of California at Los Angeles School of Medicine.

The leadership of the Scleroderma Foundation is proud to honor Dr. Khanna for his dedication to individuals impacted by this disease. He has made powerful contributions to research aimed at unraveling the cause of scleroderma, and the search to find effective treatments to enhance the lives of people living with this complex autoimmune disease.

Source: PRNewswire (2011), "Scleroderma Foundation Names University of Michigan Physician and Researcher as "Doctor of the Year"". Full news release can be found here
 
More articles :

» Research Vital Statistics and Information On Virtually Any Medicine

is a useful database of information about the prescription and over-the-counter medication, allowing you to look up the possible side effects of specific drugs and see statistics about their reported problems.If you were to look up the allergy...

» Endothelin Drugs Benefit Those With Pulmonary Hypertension

Breaking news from has reported that recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of and provides hope for treating other chronic...

» Scleroderma and Pregnancy

In an ideal world, men and women would be able to start their families with no difficulties or problems.  However, there are many issues that can complicate matters and Scleroderma and Pregnancy is one of those issues. It is very important to...

» Scleroderma Patients At Greater Risk Of Myocardial Infarction Within First Year

According to the first large population-based cohort study of its kind, patients with Systemic Sclerosis or were found to be at a greater than eightfold increased risk of having an acute (MI) during their first year after diagnosis. After that...

» Facing Life's Challenges

At 57 years of age Anne Wersching doesn’t have a single wrinkle on her face.Sitting in her lounge room in Bayswater North, Ms Wersching looks well, save for a few red marks on her cheeks.But Ms Wersching has a little-known disease called...

» L-selectin and Skin Damage in Systemic Sclerosis

L-selectin ligands are induced on the endothelium of inflammatory sites. L-selectin expression on neutrophils and monocytes may mediate the primary adhesion of these cells at sites of inflammation by mediating the leukocyte-leukocyte interactions...